GD
42
4
KR
50
5
PM
49
8
CLX
65
2
DIS
70
2
MDLZ
28
2
PRU
39
3
RL
73
5
PWR
63
3
ALL
37
3
AZO
46
3
DNB
72
4
KO
44
2
JCI
44
7
AKAM
50
2
ILMN
31
4
NEE
39
9
KLAC
45
3
WMB
58
3
CI
35
2
GD
42
4
KR
50
5
PM
49
8
CLX
65
2
DIS
70
2
MDLZ
28
2
PRU
39
3
RL
73
5
PWR
63
3
ALL
37
3
AZO
46
3
DNB
72
4
KO
44
2
JCI
44
7
AKAM
50
2
ILMN
31
4
NEE
39
9
KLAC
45
3
WMB
58
3
CI
35
2
Financhill
Back

Esperion Therapeutics 10K Form

Sell
13

ESPR
Esperion Therapeutics

Last Price:
$2.18
Seasonality Move:
18.1%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive ESPR News And Ratings

See the #1 stock for the next 7 days that we like better than ESPR

ESPR Financial Statistics

Sales & Book Value

Annual Sales: $116.3M
Cash Flow: $-35.5M
Price / Cash Flow: 0
Annual Sales: $-1.89
Price / Book: 0

Profitability

EPS (TTM): -0.64000
Net Income (TTM): $-86.8M
Gross Margin: $73.1M
Return on Equity: 0%
Return on Assets: -29.58%

Esperion Therapeutics Earnings Forecast

Key Esperion Therapeutics Financial Ratios

  • The Gross Profit Margin over the past 17 years for ESPR is 62.81%.
  • The Selling, General & Administrative Expenses for ESPR have been equal to 122.51% of Gross Profit Margin.
  • The Research & Development expenses have been 74.02% of Revenue.
  • The Interest Expense is -28.18% of Operating Income.
  • The Net Earning history of ESPR is -179.87% of Total Revenues.
  • Per Share Earnings over the last 17 years have been positive in 6 years.

Esperion Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceuticals
Sector: Health Care
Current Symbol: ESPR
CUSIP: 29664W
Website: esperion.com

Debt

Debt-to-Equity Ratio: -0.71
Current Ratio: 1.85
Quick Ratio: 1.28

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 10.16

ESPR Technical Analysis vs Fundamental Analysis

Sell
13
Esperion Therapeutics (ESPR) is a Sell

Is Esperion Therapeutics a Buy or a Sell?